Who are 11C-L-deprenyl-D2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Safinamide Methanesulfonate, Rasagiline mesylate with Levodopa, Rasagiline mesylate plus Mirapex, Azilect, Auromid, Selegiline Hydrochloride.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/11c-l-deprenyl-d2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

11C-L-deprenyl-D2 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

11C-L-deprenyl-D2 (11C-L-deprenyl-D2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine oxidase inhibitor. Area: Neurology.

phase 1 Monoamine oxidase inhibitor Monoamine oxidase B Neurology Small molecule Live · refreshed every 30 min

Target snapshot

11C-L-deprenyl-D2 (11C-L-deprenyl-D2) — Hoffmann-La Roche. Selective norepinephrine reuptake inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
11C-L-deprenyl-D2 TARGET	11C-L-deprenyl-D2	Hoffmann-La Roche	phase 1	Monoamine oxidase inhibitor	Monoamine oxidase B
Safinamide Methanesulfonate	Safinamide Methanesulfonate	Zambon SpA	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase B)
Rasagiline mesylate with Levodopa	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway
Rasagiline mesylate plus Mirapex	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors
Azilect	RASAGILINE	Teva	marketed	Monoamine Oxidase Inhibitor	5-hydroxytryptamine receptor 6	2006-01-01
Auromid	MOCLOBEMIDE		marketed	Monoamine Oxidase Inhibitors	Amine oxidase [flavin-containing] A	1990-01-01
Selegiline Hydrochloride	SELEGILINE	Somerset	marketed	Monoamine Oxidase Inhibitor	Amine oxidase [flavin-containing] B	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine oxidase inhibitor class)

Shire · 2 drugs in this class
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 11C-L-deprenyl-D2 — Competitive Intelligence Brief. https://druglandscape.com/ci/11c-l-deprenyl-d2. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab